Systemic Anticoagulation Considerations in Chronic Kidney Disease

Advances in Chronic Kidney Disease

Volumn 17, Issue 5, 2010, Pages 420-427

  Dager, William E ^a,b,c,d   Kiser, Tyree H ^a,b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d TOURO UNIVERSITY CALIFORNIA   (United States)

Author keywords

Anticoagulation; Chronic kidney disease; Direct thrombin inhibitors; Hemodialysis; Heparin; Low molecular weight heparin; Warfarin

Indexed keywords

ARGATROBAN; DABIGATRAN; DESULFATOHIRUDIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR; TINZAPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; CHRONIC KIDNEY DISEASE; FIBRINOLYSIS; HUMAN; KIDNEY FUNCTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; STROKE; THROMBOEMBOLISM;

EID: 77955801264     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2010.06.002     Document Type: Review

References (54)

1. Tveit D.P., Hypolite I.O., Hshieh P., et al. Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis 2002, 39:1011-1017.
2. Wattanakit K., Cushman M., Stehman-Breen C., et al. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 2008, 19:135-140.
3. Sood M.M., Komenda P., Sood A.R., et al. The intersection of risk and benefit: Is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis?. Chest 2009, 136:1128-1133.
4. Shlipak M.G., Fried L.F., Crump C., et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003, 107:87-92.
5. Adams M.J., Irish A.B., Watts G.F., et al. Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function. Thromb Res 2008, 123:374-380.
6. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098.
7. Naumnik B., Borawski J., Mysliwiec M. Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: A prospective study. Nephrol Dial Transplant 2003, 18:1376-1382.
8. Ambuhl P.M., Wuthrich R.P., Korte W., et al. Plasma hypercoagulability in haemodialysis patients: Impact of dialysis and anticoagulation. Nephrol Dial Transplant 1997, 12:2355-2364.
9. Remuzzi G., Marchesi D., Livio M., et al. Altered platelet and vascular prostaglandin-generation in patients with renal failure and prolonged bleeding times. Thromb Res 1978, 13:1007-1015.
10. Yoshida E., Fujimura Y., Ikeda Y., et al. Impaired high-shear-stress-induced platelet aggregation in patients with chronic renal failure undergoing haemodialysis. Br J Haematol 1995, 89:861-867.
11. Matzke G.R., Frye R.F. Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. Drug Saf 1997, 16:205-231.
12. Limdi N.A., Beasley T.M., Baird M.F., et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009, 20:912-921.
13. Dager W.E. Initiating warfarin therapy. Ann Pharmacother 2003, 37:905-908.
14. Rioux J.P., De Bortoli B., Querin S., et al. Measurement of the international normalized ratio (INR) in hemodialysis patients with heparin-locked central venous catheters: Evaluation of a novel blood sampling method. J Vasc Access 2009, 10:180-182.
15. Chan K.E., Lazarus J.M., Thadhani R., et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009, 20:2223-2233.
16. Kearon C., Ginsberg J.S., Julian J.A., et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006, 296:935-942.
17. Lim W., Dentali F., Eikelboom J.W., et al. Meta-analysis: Low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006, 144:673-684.
18. George-Phillips K.L., Bungard T.J. Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction. Pharmacotherapy 2006, 26:1479-1490.
19. Nutescu E.A., Spinler S.A., Wittkowsky A., et al. Low-molecular-weight heparins in renal impairment and obesity: Available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009, 43:1064-1083.
20. McMahon L.P., Chester K., Walker R.G. Effects of different dialysis membranes on serum concentrations of epoetin alfa, darbepoetin alfa, enoxaparin, and iron sucrose during dialysis. Am J Kidney Dis 2004, 44:509-516.
21. Brophy D.F., Carr M.E., Martin E.J., et al. The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies. J Clin Pharmacol 2006, 46:887-894.
22. Joannidis M., Kountchev J., Rauchenzauner M., et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: A randomized controlled crossover study. Intensive Care Med 2007, 33:1571-1579.
23. Reeves J.H., Cumming A.R., Gallagher L., et al. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 1999, 27:2224-2228.
24. Sagedal S., Hartmann A., Sundstrom K., et al. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant 2001, 16:987-993.
25. Arixtra (fondaparinux) prescribing information January 2010, GlaxoSmithKline, GlaxoSmithKline, Research Triangle Park, NC.
26. Warkentin T.E., Greinacher A., Koster A., et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2008, 133:340S-380S. (8th Edition).
27. Simoons M.L., Bobbink I.W., Boland J., et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: The Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol 2004, 43:2183-2190.
28. A phase II evaluation. The Rembrandt Investigators. Circulation 2000, 102:2726-2731. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity.
29. Turpie A.G., Lensing A.W., Fuji T., et al. Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Blood Coagul Fibrinolysis 2009, 20:114-121.
30. Haase M., Bellomo R., Rocktaeschel J., et al. Use of fondaparinux (ARIXTRA) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II. Nephrol Dial Transplant 2005, 20:444-446.
31. Kalicki R.M., Aregger F., Alberio L., et al. Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. Thromb Haemost 2007, 98:1200-1207.
32. Hursting M.J., Murray P.T. Argatroban anticoagulation in renal dysfunction: A literature analysis. Nephron 2008, 109:c80-c94.
33. Arpino P.A., Hallisey R.K. Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother 2004, 38:25-29.
34. Dager W.E., Dougherty J.A., Nguyen P.H., et al. Heparin-induced thrombocytopenia: Treatment options and special considerations. Pharmacotherapy 2007, 27:564-587.
35. Angiomax (bivalirudin) prescribing information December 2005, The Medicines Company, The Medicines Company, Parsippany, NJ.
36. Kiser T.H., Burch J.C., Klem P.M., et al. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2008, 28:1115-1124.
37. Hirsh J., Bauer K.A., Donati M.B., et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2008, 133:141S-159S. (8th Edition).
38. Sanderink G.J., Guimart C.G., Ozoux M.L., et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002, 105:225-231.
39. Douketis J., Cook D., Meade M., et al. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: An assessment of safety and pharmacodynamics: The DIRECT study. Arch Intern Med 2008, 168:1805-1812.
40. Polkinghorne K.R., McMahon L.P., Becker G.J. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis 2002, 40:990-995.
41. Kerr P.G., Mattingly S., Lo A., et al. The adequacy of fragmin as a single bolus dose with reused dialyzers. Artif Organs 1994, 18:416-419.
42. Perry S.L., O'Shea S.I., Byrne S., et al. A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. Thromb Haemost 2006, 96:750-755.
43. Klaeffling C., Piechottka G., Daemgen-von Brevern G., et al. Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium. Ther Drug Monit 2006, 28:375-381.
44. Bazinet A., Almanric K., Brunet C., et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res 2005, 116:41-50.
45. Naumnik B., Pawlak K., Mys'liwiec M. Unfractionated heparin but not enoxaparin causes delayed plasma PAI-1 depletion in hemodialysis patients: A prospective study. Clin Appl Thromb Hemost 2009, 15:84-91.
46. Crowther M.A., Ageno W., Garcia D., et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: A randomized trial. Ann Intern Med 2009, 150:293-300.
47. Lousberg T.R., Witt D.M., Beall D.G., et al. Evaluation of excessive anticoagulation in a group model health maintenance organization. Arch Intern Med 1998, 158:528-534.
48. Lubetsky A., Yonath H., Olchovsky D., et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: A prospective randomized controlled study. Arch Intern Med 2003, 163:2469-2473.
49. Crowther M.A., Douketis J.D., Schnurr T., et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002, 137:251-254.
50. Makris M., Greaves M., Phillips W.S., et al. Emergency oral anticoagulant reversal: The relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997, 77:477-480.
51. Deveras R.A., Kessler C.M. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002, 137:884-888.
52. Leissinger C.A., Blatt P.M., Hoots W.K., et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature. Am J Hematol 2008, 83:137-143.
53. O'Connell K.A., Wood J.J., Wise R.P., et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006, 295:293-298.
54. Yasaka M., Sakata T., Minematsu K., et al. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res 2002, 108:25-30.